EUVIMEDEUVIMED entdecken
Crossref

De novo variants in ATXN7L3 lead to developmental delay, hypotonia and distinctive facial features

Tamar Harel iD, Camille Spicher, Elisabeth Scheer, Jillian G Buchan, Jennifer Cech, Chiara Folland, Tanja Frey, Alexander M Holtz, A Micheil Innes, Boris Keren, William L Macken iD, Carlo Marcelis und 15 weitere

Brain · 01.08.2024 · 147 (8) · 2732-2744

DOI: 10.1093/brain/awae160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 16.05.2024. Verfasst von Tamar Harel und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Hadassah Medical Center, Jerusalem, Israel, 9112001. Hauptthemen laut MEDLINE: Muscle Hypotonia, Developmental Disabilities. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, ANR, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deubiquitination is crucial for the proper functioning of numerous biological pathways, such as DNA repair, cell cycle progression, transcription, signal transduction and autophagy. Accordingly, pathogenic variants in deubiquitinating enzymes (DUBs) have been implicated in neurodevelopmental disorders and congenital abnormalities. ATXN7L3 is a component of the DUB module of the Spt-Ada-Gcn5 acetyltransferase (SAGA) complex and two other related DUB modules, and it serves as an obligate adaptor protein of three ubiquitin-specific proteases (USP22, USP27X or USP51). Through exome sequencing and by using GeneMatcher, we identified nine individuals with heterozygous variants in ATXN7L3. The core phenotype included global motor and language developmental delay, hypotonia and distinctive facial characteristics, including hypertelorism, epicanthal folds, blepharoptosis, a small nose and mouth, and low-set, posteriorly rotated ears. To assess pathogenicity, we investigated the effects of a recurrent nonsense variant [c.340C>T; p.(Arg114Ter)] in fibroblasts of an affected individual. ATXN7L3 protein levels were reduced, and deubiquitylation was impaired, as indicated by an increase in histone H2Bub1 levels. This is consistent with the previous observation of increased H2Bub1 levels in Atxn7l3-null mouse embryos, which have developmental delay and embryonic lethality. In conclusion, we present clinical information and biochemical characterization supporting ATXN7L3 variants in the pathogenesis of a rare syndromic neurodevelopmental disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle HypotoniaDevelopmental DisabilitiesHumansFemaleMaleChild, PreschoolChildPhenotypeAnimalsAdolescentExome SequencingFaceInfantTranscription Factors

Stichwörter der Autor:innen

ATXN7L3SAGA complexdeubiquitinationdevelopmental delayexome sequencingintellectual disability

Substanzen

ATXN7L3 protein, humanTranscription Factors

Autor:innen und Institutionen

  • Department of Genetics, Hadassah Medical Center, Jerusalem, Israel, 9112001.
  • Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel, 9112001.
  • Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch, France.
  • Centre National de la Recherche Scientifique (CNRS), UMR7104, 67404 Illkirch, France.
  • Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, 67404 Illkirch, France.
  • Université de Strasbourg, 67404 Illkirch, France.

ORCID-Profile: Tamar Harel, William L Macken, Robert D S Pitceathly, Anita Rauch, Gianina Ravenscroft, Didier Devys, Stéphane D Vincent, László Tora

Förderung

  • Agence Nationale de la Recherche
  • ANR
  • NIH
  • MIRA
  • University of Strasbourg
  • IdEx Unistra
  • SFRI-STRAT'US project
  • EUR IMCBio

Zitieren

APA

Harel, T., Spicher, C., Scheer, E., Buchan, J. G., Cech, J., Folland, C., Frey, T., Holtz, A. M., Innes, A. M., Keren, B., Macken, W. L., Marcelis, C., Otten, C. E., Paolucci, S. A., Petit, F., Pfundt, R., Pitceathly, R. D. S., Rauch, A., Ravenscroft, G., …, & Tora, L. (2024). De novo variants in ATXN7L3 lead to developmental delay, hypotonia and distinctive facial features. Brain, 147(8), 2732-2744. https://doi.org/10.1093/brain/awae160

Vancouver

Harel T, Spicher C, Scheer E, Buchan JG, Cech J, Folland C, et al. De novo variants in ATXN7L3 lead to developmental delay, hypotonia and distinctive facial features. Brain. 2024;147(8):2732-2744. doi:10.1093/brain/awae160

BibTeX
@article{Harel2024,
  author = {Harel, Tamar and Spicher, Camille and Scheer, Elisabeth and Buchan, Jillian G and Cech, Jennifer and Folland, Chiara and Frey, Tanja and Holtz, Alexander M and Innes, A Micheil and Keren, Boris and Macken, William L and Marcelis, Carlo and Otten, Catherine E and Paolucci, Sarah A and Petit, Florence and Pfundt, Rolph and Pitceathly, Robert D S and Rauch, Anita and Ravenscroft, Gianina and Sanchev, Rani and Steindl, Katharina and Tammer, Femke and Tyndall, Amanda and Devys, Didier and Vincent, Stéphane D and Elpeleg, Orly and Tora, László},
  title = {De novo variants in ATXN7L3 lead to developmental delay, hypotonia and distinctive facial features},
  journal = {Brain},
  year = {2024},
  volume = {147},
  number = {8},
  pages = {2732--2744},
  doi = {10.1093/brain/awae160}
}
Kostenlos starten →